{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NYSE/GSK",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# GSK plc (NYSE: GSK) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is GSK plc, listed on the NYSE under the ticker GSK, with ISIN US37733W2044 and LEI 5493000HZTVUYLO1D793. Its security type is recorded as non-operating entity type (other). Its segment is not on the record. Its sector is 2834 Pharmaceutical Preparations and its jurisdiction is the United Kingdom. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 301 filings in the window from 2025-11-08 to 2026-11-08, across 164 filing days. The median gap between filing days is 1 day. The latest filing is dated 2026-11-06 and is of type results, 2 days before the record date of 2026-11-08. The NYSE median cadence gap is 6.0 days, the NYSE median latency is 4.0 days, and the NYSE median filings count is 64.0. The sector median cadence gap is 6.0 days, the sector median latency is 4.0 days, and the sector median filings count is 63.0.\n\n## Auditor\n\nThe auditor is not on the record, because the latest annual report cover carries no dei:AuditorName tag, as foreign private issuers and older filings carry none. The auditor's location is not on the record. No auditor changes are on the record.\n\n## Events and halts\n\nThe lifecycle lines on the record are listings dated 2026-09-15 and 2026-09-22. No delisting and no name change are on the record. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe record names 14 research houses on the issuer's own investor-relations page: Barclays, Berenberg, BNP Paribas Exane, Citi, Deutsche Bank, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, TD Cowen, UBS and Wolfe Research.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe vintage is sealed. Sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n9 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001131399.json (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.us-cm-kg.ai/events/NYSE/GSK (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus (coverage)\n- https://mcp.us-cm-kg.ai/record/NYSE/GSK (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NYSE/GSK",
  "coverage": {
   "count": 14,
   "houses": [
    {
     "house": "Barclays",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "Berenberg",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "BNP Paribas Exane",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "Citi",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "Deutsche Bank",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "Goldman Sachs",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "Guggenheim Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "Jefferies",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "JP Morgan",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "Morgan Stanley",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "Redburn",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "TD Cowen",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "UBS",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    },
    {
     "house": "Wolfe Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus",
     "result": "read: 14 of 30 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 3256,
     "median_cadence_gap_days": 6,
     "median_filings": 64,
     "median_latency_days": 4,
     "name": "NYSE"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "directors_dealings": 1,
    "prospectus": 2,
    "regulatory_filing": 16,
    "results": 269,
    "takeover": 13
   },
   "cadence_median_gap_days": 1,
   "filing_days": 164,
   "filings": 301,
   "latency_days": 2,
   "latest": [
    {
     "category": "6-K",
     "date": "2026-11-06",
     "source": "https://www.sec.gov/Archives/edgar/data/1131399/000165495426009585/a1986c.htm",
     "title": "6-K — GSK PUBLISHES PROVISIONAL DIVIDEND DATES",
     "type": "results"
    },
    {
     "category": "13F-HR",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/1131399/000199937126024635/xslForm13F_X02/primary_doc.xml",
     "title": "13F-HR",
     "type": "regulatory_filing"
    },
    {
     "category": "6-K",
     "date": "2026-11-02",
     "source": "https://www.sec.gov/Archives/edgar/data/1131399/000165495426009362/a4168b.htm",
     "title": "6-K — TOTAL VOTING RIGHTS",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-10-28",
     "source": "https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm",
     "title": "6-K — 3RD QUARTER RESULTS",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-10-26",
     "source": "https://www.sec.gov/Archives/edgar/data/1131399/000165495426009141/a4463a.htm",
     "title": "6-K — RIS-REZ POSITIVE PH 3 OSTEOSARCOMA DATA IN CHINA",
     "type": "results"
    }
   ],
   "latest_filing_date": "2026-11-06",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/GSK",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NYSE"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-13",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US37733W2044"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001131399.json",
    "state": "sourced",
    "value": "United Kingdom"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-08",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN US37733W2044)",
    "state": "sourced",
    "value": "5493000HZTVUYLO1D793"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001131399.json",
    "state": "sourced",
    "value": "GSK plc"
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001131399.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001131399.json",
    "state": "sourced",
    "value": "Non-operating entity type (other)"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "GSK"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [
    {
     "date": "2026-09-15",
     "source": "https://www.sec.gov/Archives/edgar/data/1131399/000119312526391619/d339440d8a12b.htm",
     "title": "8-A12B — 8-A12B"
    },
    {
     "date": "2026-09-22",
     "source": "https://www.sec.gov/Archives/edgar/data/1131399/000087666126000783/GSK092226.pdf",
     "title": "CERT — NYSE CERTIFICATION"
    }
   ],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:aa6d549f852c6a62ebc1eb688e9cc71597793ccb099c98c32d03464f36efc1b1",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NYSE/GSK",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:aa6d549f852c6a62ebc1eb688e9cc71597793ccb099c98c32d03464f36efc1b1",
 "path": "/us/NYSE/GSK",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is GSK plc, listed on the NYSE under the ticker GSK, with ISIN US37733W2044 and LEI 5493000HZTVUYLO1D793. Its security type is recorded as non-operating entity type (other). Its segment is not on the record. Its sector is 2834 Pharmaceutical Preparations and its jurisdiction is the United Kingdom. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 301 filings in the window from 2025-11-08 to 2026-11-08, across 164 filing days. The median gap between filing days is 1 day. The latest filing is dated 2026-11-06 and is of type results, 2 days before the record date of 2026-11-08. The NYSE median cadence gap is 6.0 days, the NYSE median latency is 4.0 days, and the NYSE median filings count is 64.0. The sector median cadence gap is 6.0 days, the sector median latency is 4.0 days, and the sector median filings count is 63.0.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor is not on the record, because the latest annual report cover carries no dei:AuditorName tag, as foreign private issuers and older filings carry none. The auditor's location is not on the record. No auditor changes are on the record.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The lifecycle lines on the record are listings dated 2026-09-15 and 2026-09-22. No delisting and no name change are on the record. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The record names 14 research houses on the issuer's own investor-relations page: Barclays, Berenberg, BNP Paribas Exane, Citi, Deutsche Bank, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, TD Cowen, UBS and Wolfe Research.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The vintage is sealed. Sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "9 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001131399.json"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/GSK"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NYSE/GSK"
  }
 ],
 "title": "GSK plc (GSK) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}